Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anetumab ravtansine + cisplatin + pemetrexed
- Development stage
- Preclinical
- Lead developer
- Bayer
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
A combination therapy consisting of anetumab ravtansine (an antibody-drug conjugate targeting mesothelin), cisplatin (a platinum-based chemotherapy), and pemetrexed (a folate antimetabolite). This combination targets mesothelin-expressing solid tumors through multiple mechanisms: anetumab ravtansine binds to mesothelin on tumor cells, releasing the DM4 payload that disrupts microtubule polymerization; cisplatin crosslinks DNA; and pemetrexed inhibits multiple enzymes involved in folate metabolism and DNA synthesis.
02
Targets
TS (Thymidylate synthase)MesothelinDHFR (Dihydrofolate reductase)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on anetumab ravtansine + cisplatin + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anetumab ravtansine + cisplatin + pemetrexed.